Pioneering the development
of engineered IgM antibodies
for the treatment of cancer
IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis
January 7, 2020
Expert in the research and development of apoptotic pathways and antibody drug conjugates. MOUNTAIN VIEW,…
Agonist and Bispecific IgM: Nature’s Approach to Highly Avid, Multivalent Antibodies
November 22, 2019
November, 2019 – PEGS Europe, Lisbon Bruce Keyt, PhD, Chief Scientific Officer IGM Biosciences, Inc.,…
A New Era in Cancer Therapeutics: Biologic Problems and Engineering Solutions
November 21, 2019
November, 2019 – PEGS Europe, Lisbon Daniel Chen, MD, PhD, Chief Medical Officer IGM Biosciences,…
IGM Biosciences to Present at Three Upcoming Investor Conferences
November 12, 2019
MOUNTAIN VIEW, Calif. — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on…
IGM Biosciences Announces Third Quarter 2019 Financial Results
November 7, 2019
MOUNTAIN VIEW, Calif., Nov. 7, 2019 — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology…